Serum Institute of India, Novavax in covid vaccine deal, may produce 100 crore doses1 min read 07 Aug 2020, 09:36 AM IST
The agreement is expected to support minimum of 100 crore doses of Novavax's covid vaccine for India and low- and middle-income countries
Pune-based Serum Institute of India and US-based Novavax have announced an agreement for the development and commercialization of Novavax’ COVID‑19 vaccine candidate in India and other low- and middle-income countries. The agreement is expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries, Novavax said.
Select your Category